Published in
Elsevier, Annals of Oncology, (34), p. S1278-S1279, 2023
DOI: 10.1016/j.annonc.2023.10.031
Links
Tools
LBA37 Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial
Journal article published in 2023 by
A. Gonzalez Martin,
M. J. Rubio Perez,
F. Heitz,
R. D. Christensen,
N. Colombo,
T. Van Gorp 
,
A. Oaknin,
A. Leary,
L. Gaba Garcia,
C. Lebreton,
L. M. De Sande González,
M. Romeo Marin,
A. Redondo,
M. P. Barretina Ginesta,
J. A. Perez Fidalgo
and other authors.
,
A. Oaknin,
A. Leary,
L. Gaba Garcia,
C. Lebreton,
L. M. De Sande González,
M. Romeo Marin,
A. Redondo,
M. P. Barretina Ginesta,
J. A. Perez Fidalgo
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 